Perflubutane

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Perflubutane
Accession Number
DB12821  (DB05392)
Type
Small Molecule
Groups
Approved, Investigational
Description

Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

Structure
Thumb
Synonyms
  • Decafluorobutane
  • perflubutano
  • Sonazoid
External IDs
AI-700
Categories
UNII
SE4TWR0K2C
CAS number
355-25-9
Weight
Average: 238.028
Monoisotopic: 237.98403163
Chemical Formula
C4F10
InChI Key
KAVGMUDTWQVPDF-UHFFFAOYSA-N
InChI
InChI=1S/C4F10/c5-1(6,3(9,10)11)2(7,8)4(12,13)14
IUPAC Name
decafluorobutane
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Perflubutane perfusion echocardiography has the potential to be a cost-effective and convenient alternative to nuclear perfusion imaging. Perflubutane is easy to use and echocardiographers in the clinical trials can be trained to use it after imaging only a few patients. Based on data from previous clinical trials, ultrasound enhanced with Perflubutane was able to image myocardial perfusion and obtain information that appears comparable to nuclear imaging. Acusphere's Phase 3 program is designed with the appropriate comparative standards to determine the value of Perflubutane perfusion echocardiography relative to nuclear perfusion imaging. These standards are coronary angiography, nuclear perfusion imaging, and patient outcome.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
3-Aza-2,3-Dihydrogeranyl DiphosphatePerflubutane can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidPerflubutane can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
AloglutamolAloglutamol can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

References

General References
  1. Hamilos MI, Patrianakos AP: AI-700 (Acusphere). Curr Opin Investig Drugs. 2005 Sep;6(9):956-61. [PubMed:16187696]
External Links
PubChem Compound
9638
PubChem Substance
347828991
ChemSpider
13862701
ChEBI
134964
ChEMBL
CHEMBL2104979
Wikipedia
Perfluorobutane

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingDiagnosticEsophagus1
0RecruitingDiagnosticMyocardial Ischemia1
1CompletedEducational/Counseling/TrainingChronic Obstructive Pulmonary Disease (COPD) / Congestive Heart Failure (CHF)1
1CompletedOtherHealthy Volunteers1
1RecruitingDiagnosticCutaneous Melanoma / Melanoma1
1, 2RecruitingDiagnosticCancer, Breast1
2Not Yet RecruitingDiagnosticKidney Transplant Rejection1
2RecruitingDiagnosticBlood Pressures / Cardiac Catheterizations / Echocardiography / Heart Failure, Unspecified / Heart Ventricles1
2RecruitingDiagnosticPeripheral Artery Disease (PAD)1
3CompletedDiagnosticCoronary Artery Disease1
3CompletedDiagnosticLiver Lesions1
3WithdrawnDiagnosticLiver Masses / Liver Metastasis1
4RecruitingDiagnosticLiver Diseases / Portal Hypertension1
Not AvailableRecruitingDiagnosticFocal Nodular Hyperplasia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0485 mg/mLALOGPS
logP3.63ALOGPS
logP3.48ChemAxon
logS-3.7ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity22.21 m3·mol-1ChemAxon
Polarizability9.22 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Organofluorides
Sub Class
Not Available
Direct Parent
Organofluorides
Alternative Parents
Hydrocarbon derivatives / Alkyl fluorides
Substituents
Hydrocarbon derivative / Organofluoride / Alkyl halide / Alkyl fluoride / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 18:30 / Updated on November 02, 2018 07:30